Endometrial Cancer - Pipeline Review, H1 2020

May 2020 | 1456 pages | ID: EAE7F13C98BEN
Global Markets Direct

Abstracts

Endometrial Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer – Pipeline Review, H1 2020, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.

Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 74, 66, 3, 12, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 1 and 2 molecules, respectively.

Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Endometrial Cancer - Overview
Endometrial Cancer - Therapeutics Development
Endometrial Cancer - Therapeutics Assessment
Endometrial Cancer - Companies Involved in Therapeutics Development
Endometrial Cancer - Drug Profiles
Endometrial Cancer - Dormant Projects
Endometrial Cancer - Discontinued Products
Endometrial Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Endometrial Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Endometrial Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
Endometrial Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020
Endometrial Cancer - Pipeline by Abpro Corp, H1 2020
Endometrial Cancer - Dormant Projects, H1 2020
Endometrial Cancer - Discontinued Products, H1 2020
Endometrial Cancer - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Endometrial Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Aadi Bioscience Inc
Ability Pharmaceuticals SL
Abpro Corp
Acepodia Biotech Inc
Acrotech Biopharma LLC
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Agenus Inc
Almac Discovery Ltd
Amgen Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Apollomics Inc
Arcus Biosciences Inc
Arrien Pharmaceuticals LLC
Ascenta Therapeutics Inc
AstraZeneca Plc
Bantam Pharmaceutical LLC
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
Bicycle Therapeutics Plc
Bio-Path Holdings Inc
BioMed Valley Discoveries Inc
BioNTech SE
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Byondis BV
Carrick Therapeutics Ltd
Celon Pharma SA
Celsion Corp
Checkpoint Therapeutics Inc
Clovis Oncology Inc
Compugen Ltd
Context Therapeutics LLC
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
Cue Biopharma Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Deciphera Pharmaceuticals Inc
Eisai Co Ltd
Eli Lilly and Co
Elicio Therapeutics
ENB Therapeutics LLC
Epizyme Inc
Esperance Pharmaceuticals Inc
Esperas Pharma Inc
EstryX Pharma Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
GamaMabs Pharma SA
Genmab AS
GlaxoSmithKline Plc
Gradalis Inc
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Inc Ltd
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
Immunocore Ltd
ImmunoGen Inc
Immunomedics Inc
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
Jiangsu Hengrui Medicine Co Ltd
Karyopharm Therapeutics Inc
Komipharm International Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Leap Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Mersana Therapeutics Inc
Merus NV
Millennium Pharmaceuticals Inc
Moderna Inc
Molecular Partners AG
Molecular Templates Inc
NeoTX Therapeutics Ltd
NextCure Inc
Northlake International LLC
Novartis AG
NovaTarg Therapeutics Inc
Oncoceutics Inc
Oncologie Inc
Oncology Venture U.S. Inc
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
PRISM Pharma Co Ltd
PTC Therapeutics Inc
Puma Biotechnology Inc
Samumed LLC
Sanofi
SELLAS Life Sciences Group Inc
Shanghai Junshi Bioscience Co Ltd
Splash Pharmaceuticals Inc
Spring Bank Pharmaceuticals Inc
SpringWorks Therapeutics Inc
Sutro Biopharma Inc
Syndax Pharmaceuticals Inc
Taiho Pharmaceutical Co Ltd
Unum Therapeutics Inc
Vyriad Inc
Xencor Inc
Zymeworks Inc